Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
110
days
CircRNA-mediated regulation of ferroptosis in cancer: mechanistic networks and therapeutic implications
Authors
Yuliang Zhang; Xingyu Du; Jin Liu; Yujia Guo; Xiaoxia WangShow moreShow less
Affiliations
1. Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, China; 2. Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, ChinaShow moreShow less
305
days
METTL3-mediated m⁶A methylation of E2F2 targets MCU to promote the malignant phenotype of gastric cancer cells
Authors
Huan Liu; ZhongCong Guo; Lan Li; YuXuan Dong; Nian Chen; ZhengTai YuanShow moreShow less
Affiliations
1. Department of Gastrointestinal Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha City, China; 2. Oncology Medical Center, The First Hospital of Hunan University of Chinese Medicine, Changsha City, ChinaShow moreShow less
166
days
Targeted degradation of protein in hematologic malignancies: mechanisms, therapeutic strategies, and clinical prospects
Authors
Sana Nafees; Glowi Alasiri; Mohammad Suhail Akhter; Nemat AliShow moreShow less
Affiliations
1. Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia; 2. Department of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia; 3. MLT department, College of Nursing and Health Sciences, Jazan University, Jizan, Saudi Arabia; 4. Health Research Center, Jazan University, Jizan, Saudi Arabia; 5. Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaShow moreShow less
326
days
TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming
Authors
Mengwei Zhang; Yu Wang; Siyi Li; Gengwei Huo; Yuchao He; Xiaomeng Hu; Wenshuai Chen; Xinrui Wen; Liwei Chen; Yi Luo; Peng Chen; Hua GuoShow moreShow less
Affiliations
1. Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 2. National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; 3. Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; 4. Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 5. Department of Ultrasound Diagnosis and Treatment, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaShow moreShow less
193
days
CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8 + T cells
Authors
Chunli Zhang; Qiuxia Wei; Nigmat Rahim; Gang Bian; Chaoling Wu; Jing Wang; Ping Yang; Jiahui Hua; Mingxia Zhu; Yingtong Chen; Yan Liu; Shuang Gao; Bing Hou; Weilong Zhang; Hongmei JingShow moreShow less
Affiliations
1. Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China; 2. Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China; 3. Institute of Medical Technology, Peking University Health Science Center, Peking University, Beijing, China; 4. Shanghai Antengene Corporation Limited, Shanghai, China; 5. Department of Respiratory medicine, Affiliated Hospital of Jiujiang University, Jiujiang, ChinaShow moreShow less
287
days
Targeting HDAC and proteostasis to eradicate quiescent cancer cells
Authors
Qi Jiang; Michelle Ertel; Austin Arrigo; Amjad Hijazzi; Sara Sannino; Jennifer L. Goeckeler-Fried; April Sagan; Ian Beddows; Betsy Ann Varghese; Daniel D. Brown; Wayne Stallaert; Adrian Lee; Amanda M. Clark; Hui Shen; Jeffrey L. Brodsky; Hatice U. Osmanbeyoglu; Ronald J. BuckanovichShow moreShow less
Affiliations
1. Obstetrics and Gynecology Magee-Womens Research Inst. & Foundation, Pittsburgh, USA; 2. School of Medicine, Tsinghua University, Beijing, China; 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, USA; 4. Department of Biological Sciences, University of Pittsburgh, Pittsburgh, USA; 5. Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, USA; 6. Van Andel Institute, Grand Rapids, USA; 7. Department of Computational and Systems Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA; 8. Department of Pharmacology, University of Pittsburgh, Pittsburgh, USA; 9. Department of Pathology, University of Pittsburgh, Pittsburgh, USA; 10. Department of Internal Medicine, UPMC Hillman Cancer Center, Pittsburgh, USAShow moreShow less
FAQ
How long does CANCER GENE THERAPY take to review a manuscript?
As of 2026-11-19, CrushSCI has 20 complete review records for CANCER GENE THERAPY. The fastest paper went from submission to acceptance in 102 days (The paradox of miR-107 in oncology: dual roles as a tumor suppressor and oncomiR, received 2026-02-02, accepted 2026-05-15); the slowest took 408 days. The average is 233 days and the median is 225.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
